37. Budagian V, Bulanova E, Orinska Z, Ludwig A, Rose-John S, et al. (2004) Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J.Biol.Chem. 279: 40368–40375. 38. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, et al. (2007) Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans- signaling function of neutrophils. Blood 110: 1748–1755. 39. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ (2000) Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA- induced) GH receptor proteolysis and GHBP generation. Endocrinology 141: 4342–4348. 40. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, et al. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186–1195. 41. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, et al. (2005) Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb.Chem.High Throughput.Screen. 8: 161–171. 42. Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17: 7–30. 43. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, et al. (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J.Exp.Med. 207: 1617–1624. 44. Wauman J, De CL, Vanderroost N, Lievens S, Tavernier J (2011) RNF41 (Nrdp1) controls type 1 cytokine receptor degradation and ectodomain shedding. J.Cell Sci. 124: 921–932. 45. Amit T, Bergman T, Dastot F, Youdim MB, Amselem S, et al. (1997) A membrane-fixed, truncated isoform of the human growth hormone receptor. J.Clin.Endocrinol.Metab 82: 3813–3817. 46. Hileman SM, Pierroz DD, Masuzaki H, Bjorbaek C, El-Haschimi K, et al. (2002) Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 143: 775–783. 47. Tu H, Kastin AJ, Hsuchou H, Pan W (2008) Soluble receptor inhibits leptin transport. J.Cell Physiol 214: 301–305. 48. Belmokhtar CA, Hillion J, Segal-Bendirdjian E (2001) Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mecha- nisms. Oncogene 20: 3354–3362. Regulatory Mechanisms for sOb-R Generation 49. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, et al. (2005) Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin.Cancer Res. 11: 2492–2501. 50. Hakulinen J, Keski-Oja J (2006) ADAM10-mediated release of complement membrane cofactor protein during apoptosis of epithelial cells. J.Biol.Chem. 281: 21369–21376. 51. Lizama C, Ludwig A, Moreno RD (2010) Etoposide induces apoptosis and upregulation of TACE/ADAM17 and ADAM10 in an in vitro male germ cell line model. Biochim.Biophys.Acta. 52. Wang Y, Zhang AC, Ni Z, Herrera A, Walcheck B (2010) ADAM17 activity and other mechanisms of soluble L-selectin production during death receptor- induced leukocyte apoptosis. J.Immunol. 184: 4447–4454. 53. Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R (2010) Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc.Natl.Acad.Sci.U.S.A 107: 17391–17396. 54. Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, et al. (2010) Leptin therapy in insulin-deficient type I diabetes. Proc.Natl.Acad.Sci.U.S.A 107: 4813–4819. 55. Yu X, Park BH, Wang MY, Wang ZV, Unger RH (2008) Making insulin- deficient type 1 diabetic rodents thrive without insulin. Proc.Natl.Acad.S- ci.U.S.A 105: 14070–14075. 56. Kratzsch J, Lammert A, Bottner A, Seidel B, Mueller G, et al. (2002) Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence. J.Clin.Endocrinol.Metab 87: 4587–4594. 57. Bacart J, Leloire A, Levoye A, Froguel P, Jockers R, et al. (2010) Evidence for leptin receptor isoforms heteromerization at the cell surface. FEBS Lett. 584: 2213–2217. 58. White DW, Kuropatwinski KK, Devos R, Baumann H, Tartaglia LA (1997) Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. J.Biol.Chem. 272: 4065–4071. 59. Uotani S, Bjorbaek C, Tornoe J, Flier JS (1999) Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 48: 279–286. 60. Duksin D, Bornstein P (1977) Impaired conversion of procollagen to collagen by fibroblasts and bone treated with tunicamycin, an inhibitor of protein glycosylation. J.Biol.Chem. 252: 955–962. 61. Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, et al. (2006) Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat.Med. 12: 917–924. PLoS ONE | www.plosone.org 14 April 2012 | Volume 7 | Issue 4 | e34787